FAQ: Cybin Inc. Annual Meeting Voting Results and Company Overview

What were the key results from Cybin’s annual shareholder meeting?

The meeting held on August 18, 2025, had 90 shareholders represented in person or by proxy, holding 11,264,212 common shares, which accounted for 48.92% of the company’s issued and outstanding common shares as of the record date.

What type of company is Cybin Inc.?

Cybin is a clinical-stage neuropsychiatry company developing next-generation mental healthcare treatments, specifically focusing on breakthrough neuropsychiatry solutions for mental health conditions with large unmet needs.

What treatments is Cybin currently developing?

Cybin is developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder.

Where is Cybin operational?

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

How can investors access the latest news and updates about Cybin?

The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.

What is the significance of Cybin’s approach to mental health treatment?

Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results, addressing the large unmet need for people suffering from mental health conditions.

Where can I find the full press release about the annual meeting results?

The full press release can be viewed at https://ibn.fm/cLMeA.

What additional compounds does Cybin have in its research pipeline?

The company has a research pipeline of investigational, 5-HT-receptor focused compounds beyond its main development programs for depression and anxiety disorders.